Efzofitimod: a novel anti-inflammatory agent for sarcoidosis.

IF 1.4 4区医学 Q4 RESPIRATORY SYSTEM Sarcoidosis, Vasculitis, and Diffuse Lung Diseases Pub Date : 2023-03-28 DOI:10.36141/svdld.v40i1.14396

Robert P Baughman, Vis Niranjan, Gennyne Walker, Christoph Burkart, Suzanne Paz, Yeeting Chong, David Siefker, Eileen Sun, Leslie Nangle, Sarah Forster, Michael Muders, Carol Farver, Elyse Lower, Sanjay Shukla, Daniel A Culver

{"title":"Efzofitimod: a novel anti-inflammatory agent for sarcoidosis.","authors":"Robert P Baughman, Vis Niranjan, Gennyne Walker, Christoph Burkart, Suzanne Paz, Yeeting Chong, David Siefker, Eileen Sun, Leslie Nangle, Sarah Forster, Michael Muders, Carol Farver, Elyse Lower, Sanjay Shukla, Daniel A Culver","doi":"10.36141/svdld.v40i1.14396","DOIUrl":null,"url":null,"abstract":"<p><p>Efzofitimod is a first-in-class biologic based on a naturally occurring splice variant of histidyl-tRNA synthetase (HARS) that downregulates immune responses via selective modulation of neuropilin-2 (NRP2). Preclinical data found high expression of NRP2 in sarcoidosis granulomas. Treatment with efzofitimod reduced the granulomatous inflammation induced by P. acnes in an animal model of sarcoidosis. A dose escalating trial of efzofitimod in sarcoidosis with chronic symptomatic pulmonary disease found that treatment with efzofitimod was associated with improved quality of life with a trend towards reduced glucocorticoid use and stable to improved pulmonary function. These studies have led to a large Phase 3 trial of efzofitimod in symptomatic pulmonary sarcoidosis.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/01/SVDLD-40-11.PMC10099656.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36141/svdld.v40i1.14396","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 3

Abstract

Efzofitimod is a first-in-class biologic based on a naturally occurring splice variant of histidyl-tRNA synthetase (HARS) that downregulates immune responses via selective modulation of neuropilin-2 (NRP2). Preclinical data found high expression of NRP2 in sarcoidosis granulomas. Treatment with efzofitimod reduced the granulomatous inflammation induced by P. acnes in an animal model of sarcoidosis. A dose escalating trial of efzofitimod in sarcoidosis with chronic symptomatic pulmonary disease found that treatment with efzofitimod was associated with improved quality of life with a trend towards reduced glucocorticoid use and stable to improved pulmonary function. These studies have led to a large Phase 3 trial of efzofitimod in symptomatic pulmonary sarcoidosis.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

依佐非莫德:一种治疗结节病的新型抗炎药。

efzofimodd是一种一流的生物制剂，基于一种天然存在的组氨酸- trna合成酶(HARS)剪接变体，通过选择性调节神经磷脂-2 (NRP2)下调免疫反应。临床前数据发现NRP2在结节病肉芽肿中高表达。用头孢非莫特治疗减少肉芽肿性炎症引起的痤疮在一个动物模型的结节病。一项剂量递增的依佐非莫德治疗结节病合并慢性症状性肺病的试验发现，依佐非莫德治疗与生活质量的改善有关，有减少糖皮质激素使用的趋势，并稳定地改善肺功能。这些研究导致了一项大型的3期试验，用于治疗有症状的肺结节病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 医学-呼吸系统

CiteScore

2.20

自引率

6.20%

发文量

期刊介绍： Sarcoidosis Vasculitis and Diffuse Lung Disease is a quarterly journal founded in 1984 by G. Rizzato. Now directed by R. Baughman (Cincinnati), P. Rottoli (Siena) and S. Tomassetti (Forlì), is the oldest and most prestigious Italian journal in such field.